Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors
2022 · Critical Reviews in Oncology/Hematology · 12 citations
https://doi.org/10.1016/j.critrevonc.2022.103881
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
234
Citations
8
h-index
7
i10-index
Marco Donatello Delcuratolo is an academic researcher from Casa Sollievo della Sofferenza. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment. The author has an h-index of 8, co-authored 23 publications.
ORCID: 0000-0003-3151-9166https://doi.org/10.1016/j.critrevonc.2022.103881
https://doi.org/10.1038/s41416-025-03058-6
Click to start Chat